Vitгіria 3-flt Access

: Define FLT-3 and its shift from a purely leukemic marker to a target in solid tumor immunology.

: Tabulate existing FDA-approved inhibitors and their efficacy in solid vs. liquid tumors.

: Describe how FLT-3 signaling drives hematopoietic cell proliferation and why mutations (like FLT3-ITD) lead to poor prognosis in acute myeloid leukemia (AML).

: Investigate the Flt-3/Flt-3L signal path in the microenvironment of solid tumors. Research suggests its role in modulating dendritic cells (DCs) and stimulating immune responses like immunogenic cell death. 2. Therapeutic Targeting & Drug Delivery

The phrasing "Vitória 3-FLT" suggests a context related to or biotechnology , likely referring to the FLT-3 (FMS-like tyrosine kinase-3) receptor. FLT-3 mutations are critical markers in acute leukemias and are increasingly targeted in the treatment of solid tumors .